Form 4: Zivo Bioscience CEO John Payne Acquires Shares and Warrants in Open Market
SEC Form 4 Filing
Zivo Bioscience's CEO, John Bernard Payne, purchased common stock and warrants in the company on October 16, 2024.
Summary
- On October 16, 2024, John Bernard Payne, the President and CEO of Zivo Bioscience, Inc., acquired 6,343 shares of common stock at a price of $15.76 per share.
- Following this transaction, Payne directly owns 7,909 shares of Zivo Bioscience common stock.
- Payne also acquired 634 common stock warrants with an exercise price of $15.765, expiring on October 15, 2029.
- These warrants are exercisable immediately as of October 16, 2024.
- Payne directly owns 634 of these warrants.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The CEO's purchase is a mildly positive signal, but the document itself is simply a factual report.
Positives
- The CEO's purchase of shares and warrants could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's value and future performance. Purchases are generally seen as a positive signal.
Stakeholder Impact
- The CEO's stock purchase may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/16/2024 | Date of transaction: CEO John Payne acquired common stock and warrants. |
| 10/15/2029 | Expiration date of the acquired warrants. |
Keywords
Zivo Bioscience, John Payne, Insider Trading, Form 4, Stock Acquisition, Warrants, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.